(4 ug/d in a 40 kg girl). In the current study we asked whether the growth stimulation at the dose of 100 ng/kg/d would be sustained durlng a 6 month period and whether bone age advancement would be accelerated. We randomly assigned 16 girls with Turner's syndrome, age 5 to 15 y, to treatment wlth 100 ng/kg/d EE2 or placebo for 6 months, after observing basal growth for 2 months.
We assessed growth by the 4-week lower leg growth rate (LLGR), and by height measurements, and we determined bone age at the beginning and end of treatment. The results are shown below.
(mean + SE) LLGR All data is exoressed as mean + SEM. The oredominant metabolite formed by both' fetal and maternal tissue was 1,25. There were no differences between fetal and maternal synthesis rates for either 1,25 or 24,25. However, these synthesis rates, when extrapolated to account for differences in 1) maternal and fetal renal mass and 2) maternal and fetal plasma volume, could wholly account for the fetal plasma levels and transplacental gradients of these metabolites observed in vivo. LHRHa suppresses both gonadotropin pulsations and sex steroids and slows height velocity (HV) in patients with CPP. To evaluate GH's role in this slowing of growth, sleep induced GH secretion (20 min samples, 10 PM -2 AM) and SOMC (10 PM) were measured in 9 pre-adrenarchal girls with CPP (ages at onset 1.6-6.3 yrs, M=3.8; bone ages advanced a mean of 3.7 yrs). Therapy suppressed nonadotropin pulsations, response to LHRH, estradiol and maturation indices in all ~atients. Growth velocity fell from 14.4 f 1.7 cm/yr (Mean f SEM, all measurements) pretherapy to 8.7 * 1.4 after 6 mas of therapy (p=0.0005).
DECREASE IN GROWTH HORMONE (GH) AND SOMATOMEDIN C (SOMC) DURING LHRH AGONIST (LHRHa
SOMC levels decreased from 3.1 f 0.7 IU/ml pretherapy to 1.3 f 0.2 at 3 mos (p=0.009) and 1.4 f 0.2 at 6 mos (p=0.007).
Nocturnal peak GH levels fell from 25.4 * 6.8 ng/ml pretreatment to 9.1 * 1.7 at 3 mos (p < 0.01) and 7.5 * 1.1 at 6 mos of therapy (p 10.01). Total GH secreted during the 4 hr interval decreased a mean of 58% at 3 mos and 48% at 6 mos compared to pretreatment. The accelerated HV in CPP patients under 6 yrs is associated with increased GH and SOMC production. With LHRHa induced suppresion of gonadal steroids, both HV and GH and SOMC production are decreased. These data indicate the importance of prenatal detection and treatment of the hypothyroid fetus.
LOW DOSE ETHINYL ESTRADIOL (EE2) TREATMENT OF
49 1 TURNER'S SYNDROME. Abdollah Sadeghi-Nejad, Anna
Binkiewicz and Boris Senior. Tufts University School of Medicine, New England Medical Center, Boston.
Short term studies in children with Turner's syndrome showed that EE2 in a dose of 100 ng/kg/day enhanced the rate of ulnar growth whereas a smaller dose was less effective and larger doses were inhibitory (Ross, et al, New Engl J Med m : 1 1 0 4 , 1983). We therefore treated 11 such patients (bone ages 8-15 years) with EE2 100 ng/kg/day for 3-12 months. Seven who had previously been treated with conventional doses of estrogen were taken off therapy for the preceding 3 months.
All 4 previously untreated patients exhibited breast changes on therapy. Bone maturation did not accelerate and Somatomedin C levels did not increase. Only the 3 patients with the lowest bone ages showed an appreciable growth response with the youngest showing the greatest enhancement.
Bone iecently, elimination of ~B G has been reported to result in higher binding affinity of corticosterone (6) to mineralocorticoid receptor(MR). We have studied binding affinities of rat kidney MR by cytosol and tissue slice methods after complete perfusion in situ. To estimate the degree of serm contamination in the cytosol, rat serum CBG and albmin level in cytosol were assayed by RIA. Perfused kidney cytosol contained less than 0.1 ul per ml serm contamination. In cytosol and slice experiments without blockade of the glucocorticoid receptor (GR) , both Type I and I1 3~-aldosterone binding sites were present, indicated by the curvilinear pattern of Scatchard analysis. With RU-28362 as GR blockade, Scatchard plots were rectil inear. In perfused cytosol , all the corticosteroids tested (aldosterone, deoxycorticosterone, B, cortisol , dexamethasone) bound to MR with the same affinity in the presence of RU-28362, while non-perfused cytosol showed steroid specificity similar to those previously reported. Addition of increasing amount of rat serum to perfused cytosol decreased the binding of B to MR, indicating that B was bound to CBG, thus decreasing the availability of B for MR-binding. Slices of well-perfused kidney showed steroid specificities similar to the non-perfused cytosol .
